CD274 and neoplasm: Of the 23 studies analyzed, three subsequent-line and one first-line studies in the A + I group involving 183 patient reported subgroup efficacy analysis of ORR according to the PD-L1 expression level in tumors, which resulted in a pooled ORR of 47% for the PD-L1-positive tumor and 28% for the PD-L1-negative tumor.